Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nacresertib in Healthy Adult Japanese Subjects
NCT07600762Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing Nacresertib with Placebo for Nacresertib (2 arms). Primary endpoints: Maximum Observed Plasma Concentration up to 9 Days, Time to Cmax up to 9 Days and 5 more. Started Apr 2026; status: completed.
02
Drugs
nacresertib
Beyond the preview
Go deeper on NCT07600762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600762.